Introduction
============

Lung cancer is the leading cause of cancer-associated mortality (accounting for \~13% of all diagnosed cancers), with \~1.8 million new cases in 2012 ([@b1-ol-0-0-6300]). Between 2011 and 2013, the lung cancer mortality rate increased by 464.84% in China, and this continued to increase ([@b2-ol-0-0-6300]). Non-small cell lung cancer (NSCLC) constitutes almost 85% of all lung cancers and is usually diagnosed an advanced stage ([@b3-ol-0-0-6300]). Surgery followed by chemoradiotherapy is the most commonly adopted method for locally advanced NSCLC, but the efficacy is diverse across different patients ([@b4-ol-0-0-6300]). In previous years, immunotherapy became an optional therapeutic for numerous types of cancers, including melanoma and lung cancer, through sustained activation of the immune system ([@b5-ol-0-0-6300],[@b6-ol-0-0-6300]). Certain immune checkpoint inhibitors have been shown to significantly improve the prognosis of a number of cancers, including cytotoxic T-lymphocyte antigen 4, and nivolumab may prolong the median survival time of patients with melanoma and NSCLC by 2--4 and 6--9 months, respectively ([@b7-ol-0-0-6300]). However, the morbidity and mortality rate of NSCLC remains high, and additional molecular biology studies are required for more precise treatment and earlier diagnosis.

Next generation RNA sequencing (RNA-Seq) is becoming a popular technology for the quantification of RNA, including mRNA (such as microRNA) and noncoding RNA (such as long noncoding RNA). Variation of genomic structure, including alternative splicing (AS) and single nucleotide polymorphisms, can also be detected by RNA-Seq. Compared with gene microarray, the most evident advantage of RNA-Seq is its ability to detect the expression values of low abundance as well as novel transcripts ([@b8-ol-0-0-6300]). Previous studies of NSCLC, based on RNA-Seq have been conducted and successfully identified numerous potential targets, involved in the progression or suppression of cancer. Riccardo *et al* identified the adenosine A3 receptor as a valuable target for NSCLC, based on the combination of gene fusion and differential expression analysis through RNA-Seq ([@b9-ol-0-0-6300]). In the previous study by Han *et al*, via RNA-Seq analysis, chromobox 3 and cellular retinoic acid-binding protein 2 were also considered to contribute to the progression of NSCLC ([@b10-ol-0-0-6300]).

Compared with differential expression analysis at the gene level, exon level analysis may improve analysis of disease stages ([@b11-ol-0-0-6300]). The present study aimed to identify the potential targets of NSCLC, through the combined analysis of differential expression and AS, and based on the RNA-Seq dataset from the Gene Expression Omnibus (GEO). This may be helpful for the precise treatment of NSCLC, as well as early diagnosis.

Materials and methods
=====================

### RNA-Seq dataset

The RNA-Seq dataset (GSE68795) in the present study was obtained from GEO (<http://www.ncbi.nlm.nih.gov/geo/>), which was accumulated by Durrans *et al* ([@b12-ol-0-0-6300]). A total of 17 samples were included, containing three immature monocytic myeloid cell (IMMC) samples, two epithelial cell (Epi) samples and two neutrophil (Neu) samples from lung cancer patients, as well as three IMMC samples, three Epi samples and four Neu samples from adjacent normal lung tissues. Illumina HiSeq 2000 (Illumina, Inc., San Diego, CA, USA) was used for the sequencing process. Briefly, total RNA was extracted from flow cytometry sorted cells; TruSeq RNA Sample Preparation kit (Illumina, Inc.) was used for the preparation of cDNA libraries from 15--35 ng RNA; cDNA libraries that passed size and purity check were retained for the following sequencing. Single-end 51 bp short sequences (reads) were generated for the IMMC and Neu samples, while paired-end 102 bp reads were generated for the Epi samples, in lung cancer and adjacent normal lung tissues.

### Reads mapping and assembling

Quality control of raw reads was conducted using FastQC software version 1.3, which was developed by Andrews ([@b13-ol-0-0-6300]), with the default parameters, i.e., reads with a quality score \<10 and N \>5% were discarded. The remaining reads were mapped to the UCSC genome (version GRCh37/hg19) through TopHat (2.1.0.Linux_x86_64) ([@b14-ol-0-0-6300]), a fast splice junction mapper for RNA-Seq reads, with no more than 2 mismatches in 25 bp segments. Cufflinks ([@b14-ol-0-0-6300]) (2.2.1.Linux_x86_64) was used for the assembly of the mapped reads, which allowed for the identification of novel transcripts, and fragments per kilobase of exon per million fragments mapped (FPKM) representation of gene expression value was obtained.

### Differential expression analysis

Cuffdiff of Cufflinks was used to test the significance of differential expression of genes based on FPKM. Genes with fold change (FC) \>2 (upregulated) or \<0.5 (downregulated), and false discovery rate (FDR) adjusted for P\<0.05, were considered to be differentially expressed.

### Differential alternative splicing analysis

The replicate multivariate analysis of transcript splicing (rMATS) ([@b15-ol-0-0-6300]), developed by Shen et al, was used to screen differential alternative splicing genes across samples. The mapping results (in bam format) were submitted to rMATS. Annotation of genes (in GTF format) was obtained from the UCSC and used for the screening of known splicing sites. Finally, five main alternative splicing types, including skipping exon (SE), retention intron (RI), alternative 5′splice site (A5SS), alternative 3′splice site (A3SS) and mutually exclusive exons (MXE), which satisfied the criteria of FDR \<0.1, were screened out as DAS genes.

### Functional enrichment analysis

The DE and DAS genes were submitted to the Database for Annotation, Visualization and Integrated Discovery (DAVID; <https://david.ncifcrf.gov/>) ([@b16-ol-0-0-6300]) for the analysis of enrichment of gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. P\<0.05 was considered to indicate a statistically significant difference for the screening of significant GO terms and pathways.

Results
=======

### RNA-Seq landscape

The average number of reads obtained from the RNA-Seq dataset was 60242792, and at least 35 million reads were prepared for every sample, as shown in [Table I](#tI-ol-0-0-6300){ref-type="table"}. The clean reads were mapped to the human genome (hg19) by TopHat and 86.50--91.90% unique mapped rates were obtained across all samples. These were used for the following analysis.

### Differential expression analysis

The unique mapped reads were assembled into transcripts by cufflinks, and FPKM values were obtained to quantify the mRNA expression level. Based on the criteria of FC \>2 or \<0.5, and FDR adjusted P\<0.05, umerous genes were revealed to be differential expression in tumor samples compared with normal samples.

In Epi tumor samples, a total of 1,624 DE genes were identified, which contained 915 downregulated and 709 upregulated genes. However, in IMMC tumor samples, 1,593 DE genes (639 downregulated and 954 upregulated genes) were obtained. In Neu tumor samples, 1,672 DE genes were obtained, which consisted of 1,141 downregulated and 1,672 upregulated genes. Furthermore, as shown in [Fig. 1](#f1-ol-0-0-6300){ref-type="fig"}, 111 overlapping genes were identified among those three groups of DE genes, and 91 of those overlaps were consistently upregulated or downregulated across all three types of NSCLC tumor cells.

### AS in NSCLC tumor samples

Through AS, a mRNA precursor may result in multiple mature mRNAs with different functions. In the present study, the significant DAS genes were identified for the tumor samples compared with the normal ones through rMATS, with the threshold of FDR \<0.1. Notably, alternative splicing of genes in Neu tumor samples was not found to be significantly different compared with Neu normal samples. A total of 2,130 and 1,713 DAS genes were identified in Epi and IMMC tumor samples, respectively. In total, 272 overlapping genes were screened out between the two lists of DAS genes.

A total of 5 types of AS events were identified, including A3SS, A5SS, MXE, RI and SE. As shown in [Fig. 2](#f2-ol-0-0-6300){ref-type="fig"}, SE is the most prevalent AS event in Epi and IMMC tumor samples, and accounts for 84.00 and 79.28% of all the AS events in Epi and IMMC, respectively. RI is the least prevalent AS event, which only accounts for 1.64 and 2.80% of all the AS events in Epi and IMMC, respectively.

### GO and pathway analysis

Functional enrichment analysis based on the DAVID identified a number of significantly enriched GO terms and KEGG pathways in DE and DAS genes. The top five most significant GO terms of DE genes of the three groups of NSCLC tumor samples are listed in [Table II](#tII-ol-0-0-6300){ref-type="table"}. As shown in [Table II](#tII-ol-0-0-6300){ref-type="table"}, biological processes associated with the cell and immune system were significantly enriched (P\<0.05) in the DE genes of all the three types of NSCLC tumor samples. Enriched pathways of DE genes of Epi, IMMC and Neu tumor samples are listed in [Tables III](#tIII-ol-0-0-6300){ref-type="table"}, [IV](#tIV-ol-0-0-6300){ref-type="table"} and [V](#tV-ol-0-0-6300){ref-type="table"}, respectively. Similar to the enriched GO terms, those pathways were mainly involved in the dysregulation of cell division and abnormal activity of the immune and inflammatory systems.

For DAS genes in Epi and IMMC tumor samples, their enriched GO terms are shown in [Fig. 3](#f3-ol-0-0-6300){ref-type="fig"}, which was obtained by submitting the DAVID result to the WEGO website (<http://wego.genomics.org.cn/cgi-bin/wego/index.pl>), and their enriched KEGG pathways are shown in [Fig. 4](#f4-ol-0-0-6300){ref-type="fig"}. As expected, those DAS genes were also involved in cell and immune abnormality. The insulin signaling pathway and oxidative phosphorylation, which were associated with substance metabolism and were not revealed by DE genes, were also found to be significantly enriched (P\<0.05) in Epi and IMMC tumor samples, respectively. DE and DAS genes may be complementary in the understanding of mechanisms of NSCLC.

Discussion
==========

Lung cancer remains the leading cause of cancer-associated mortality in recent years, and its main type is NSCLC ([@b17-ol-0-0-6300]). An increasing number of studies about NSCLC have been emerging and numerous potential biomarkers for the early diagnosis or treatment of NSCLC have been identified subsequent to the development of molecular biology technologies. However, the mechanisms of NSCLC remain largely unknown, and additional studies are required to improve its prognosis. In the present study, through re-analysis of the RNA-Seq dataset from the GEO database, the significant DE and DAS genes were screened out in three types of NSCLC tumor samples (Epi, IMMC and Neu), compared with the corresponding normal samples, and their enriched GO terms and KEGG pathways were obtained. The present study aimed to provide results to help with the development of therapeutic methods and drugs for NSCLC.

The rapid growth of RNA-Seq provides the chance to observe variation in the genome at the exon level, and screening of alternative splicing is one of its important applications ([@b18-ol-0-0-6300]). AS is an important mechanism that could result in proteins with different functions from one mRNA precursor, and it has been shown to affect the status of numerous diseases. AS events involving exons 15--19 of *d\'Origine nantais* tyrosine kinase have been screened out in lung cancer ([@b19-ol-0-0-6300]). In addition, the T cell factor 4K AS isoform was found to improve the prognosis of NSCLC by suppressing the proliferation and metastasis of tumor cells ([@b20-ol-0-0-6300]). In the present study, significant alternative splicing was not observed in any genes in the Neu tumor samples compared with the normal samples. Numerous AS genes were identified in Epi and IMMC tumor samples, which may indicate the differences of those three types of cells in the inducement of NSCLC.

In accordance with previous studies, SE is the most prevalent AS event, while RI is the least prevalent AS event in Epi and IMMC tumor samples ([@b21-ol-0-0-6300],[@b22-ol-0-0-6300]). A total of 272 genes demonstrated alternative splicing in Epi and IMMC tumor samples, and this may be an indication of the important roles of those genes in the progression of NSCLC. Compared with AS analysis, numerous DE genes were identified in all three types of tumor samples, and 111 overlapping genes were screened out. One of the significant differences between the DE genes and DAS genes is the involvement of substance metabolism-associated pathways of DAS genes, including the insulin signaling pathway and oxidative phosphorylation. Insulin-like growth factor (IGF-1R) performs important roles through its downstream signaling in a number of solid tumors, including NSCLC ([@b23-ol-0-0-6300]). Furthermore, IGF-1R affects cisplatin and radiation resistance in lung cancer ([@b24-ol-0-0-6300]). In addition, oxidative stress/activity is affected by IGF-1R in numerous diseases, resulting in the dysregulation of biosystems, such as in cancer or neurodegeneration ([@b25-ol-0-0-6300],[@b26-ol-0-0-6300]). DE and DAS analysis revealed a number of common GO terms and pathways, and the primary terms and pathways were cell or immune-associated. These have been investigated in numerous studies and were confirmed to play important roles in the development of numerous types of cancers, including lung cancer, gastric cancer and liver cancer ([@b27-ol-0-0-6300]--[@b29-ol-0-0-6300]).

Based on the integrated analysis of DE and DAS, alternative splicing was identified by leucine-rich repeat kinase 2 (LRRK2) in Epi and IMMC tumor samples, and was consistently downregulated in all three types of tumor cells. LRRK2 is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region. LRRK2 has been shown to play important roles in neurodegeneration diseases, including Parkinson\'s disease ([@b30-ol-0-0-6300]--[@b32-ol-0-0-6300]). The role of LRRK2 in cancer development remains unclear; however, certain indirect associations were identified ([@b33-ol-0-0-6300]). For example, through disrupting the activation of the proto-oncogene MET, LRRK2 may prevent tumor cell proliferation ([@b34-ol-0-0-6300]). Therefore, it may be a novel target for NSCLC.

In conclusion, through the combined analysis of DE and DAS, potential targets for NSCLC were screened out. Furthermore, DE and DAS may be complementary for understanding the mechanisms of NSCLC. The present study may be helpful in the diagnosis and treatment of NSCLC.
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###### 

Mapping overview of all the RNA-Sequencing experiments.

  Sample     All reads    Mapped reads   Mapped rates, %   Unique mapped   Unique mapped rates, %
  ---------- ------------ -------------- ----------------- --------------- ------------------------
  Adj-Epi1     97717750     92115270     94.3                87061215      89.1
  Adj-Epi2     63907228     58725212     91.9                55272496      86.5
  Adj-Epi3   123019030    116594941      94.8              110088025       89.5
  Adj-IMM1     40304691     38809145     96.3                37030002      91.9
  Adj-IMM2     36685339     35109464     95.7                33284563      90.7
  Adj-IMM3     44679997     42067287     94.2                40025779      89.6
  Adj-Neu1     49967221     47183219     94.4                45452825      91.0
  Adj-Neu2     50458780     47159700     93.5                44872985      88.9
  Adj-Neu3     53402957     50511053     94.6                48090506      90.1
  Adj-Neu4     52277703     49603994     94.9                47551180      91.0
  Tum-Epi1   106711340    101588228      95.2                95969883      89.9
  Tum-Epi2     94931814     90391800     95.2                85487063      90.1
  Tum-IMM1     45344289     43038591     94.9                41037840      90.5
  Tum-IMM2     42060455     40620197     96.6                38638529      91.9
  Tum-IMM3     35570701     33745251     94.9                32229614      90.6
  Tum-Neu1     37106424     34076868     91.8                32442881      87.4
  Tum-Neu2     49981740     47119502     94.3                44980801      90.0

Epi, epithelial cell; Adj, adjacent; IMM, immature monocyte; Neu, neutrophil; Tum, tumor.

###### 

Top five most significantly enriched GO terms of differential expression genes of the three groups of non-small cell lung cancer samples.

  Category       GO name                     P-value
  -------------- --------------------------- --------------
  Epi samples                                
    BP           Response to wounding        9.39×10^−15^
    CC           Extracellular space         8.69×10^−14^
    BP           Cell adhesion               2.36×10^−11^
    BP           Biological adhesion         2.59×10^−11^
    CC           Cell fraction               6.12×10^−11^
  IMMC samples                               
    BP           Immune response             3.22×10^−10^
    BP           Response to wounding        3.36×10^−7^
    BP           Cell division               2.27×10^−6^
    CC           Plasma membrane part        6.03×10^−6^
    BP           Mitosis                     6.98×10^−6^
  Neu samples                                
    BP           Cell adhesion               1.29×10^−10^
    BP           Biological adhesion         1.50×10^−10^
    MF           GTPase regulator activity   1.90×10^−10^
    MF           Nucleoside-triphosphatase   4.24×10^−10^
    CC           Plasma membrane part        5.47×10^−10^

BP, biological process; MF, molecular function; CC, cellular component; GO, gene ontology.

###### 

Kyoto Encyclopedia of Genes and Genomes pathways of differential expression genes in epithelial cell tumor samples.

  Pathway name                                      Gene number   P-value
  ------------------------------------------------- ------------- -------------
  ECM-receptor interaction                          29            1.64×10^−9^
  Complement and coagulation cascades               21            4.45×10^−6^
  Biosynthesis of unsaturated fatty acids           10            1.09×10^−4^
  Dilated cardiomyopathy                            20            1.04×10^−3^
  Focal adhesion                                    34            1.51×10^−3^
  PPAR signaling pathway                            16            2.02×10^−3^
  Hematopoietic cell lineage                        18            3.08×10^−3^
  Pathways in cancer                                48            3.29×10^−3^
  Prion diseases                                    10            4.92×10^−3^
  Hypertrophic cardiomyopathy                       17            6.63×10^−3^
  Arrhythmogenic right ventricular cardiomyopathy   15            1.30×10^−2^
  Cell adhesion molecules                           22            1.47×10^−2^
  Ether lipid metabolism                              9           1.63×10^−2^
  Systemic lupus erythematosus                      17            2.70×10^−2^
  Basal cell carcinoma                              11            3.58×10^−2^
  MAPK signaling pathway                            36            3.66×10^−2^
  Synthesis and degradation of ketone bodies          4           4.86×10^−2^
  Terpenoid backbone biosynthesis                     5           4.99×10^−2^

ECM, extracellular matrix; PPAR, peroxisome proliferator-activated receptor; MAPK, mitogen-activated protein kinase.

###### 

Kyoto Encyclopedia of Genes and Genomes pathways of differential expression genes in immature monocytic myeloid cell tumor samples.

  Pathway name                             Gene number   P-value
  ---------------------------------------- ------------- -------------
  Hematopoietic cell lineage               25            7.50×10^−7^
  DNA replication                          13            7.02×10^−5^
  Cell cycle                               26            2.25×10^−4^
  Cytokine-cytokine receptor interaction   42            7.78×10^−4^
  Cell adhesion molecules                  25            1.26×10^−3^
  ECM-receptor interaction                 18            1.95×10^−3^
  Purine metabolism                        25            9.05×10^−3^
  Chemokine signaling pathway              29            9.52×10^−3^
  Pantothenate and CoA biosynthesis          6           1.02×10^−2^
  Aminoacyl-tRNA biosynthesis              10            1.29×10^−2^
  Bladder cancer                           10            1.51×10^−2^
  PPAR signaling pathway                   13            2.75×10^−2^
  Pyrimidine metabolism                    16            3.30×10^−2^
  Viral myocarditis                        13            3.36×10^−2^
  Axon guidance                            20            3.44×10^−2^
  Pathways in cancer                       42            3.80×10^−2^
  Focal adhesion                           28            3.92×10^−2^

PPAR, peroxisome proliferator-activated receptor; ECM, extracellular matrix; CoA, coenzyme A; tRNA, transfer RNA.

###### 

Kyoto Encyclopedia of Genes and Genomes pathways of differential expression genes in neutrophil tumor samples.

  Pathway name                                      Gene number   P-value
  ------------------------------------------------- ------------- -------------
  Focal adhesion                                    61            4.81×10^−7^
  Regulation of actin cytoskeleton                  62            2.59×10^−6^
  Fc gamma R-mediated phagocytosis                  34            5.94×10^−6^
  Chemokine signaling pathway                       53            2.67×10^−5^
  Leukocyte transendothelial migration              37            5.92×10^−5^
  ECM-receptor interaction                          29            7.03×10^−5^
  Axon guidance                                     37            4.28×10^−4^
  Pathogenic *Escherichia coli* infection           20            1.01×10^−3^
  Hypertrophic cardiomyopathy                       26            1.40×10^−3^
  Adherens junction                                 24            1.71×10^−3^
  Pathways in cancer                                73            2.62×10^−3^
  Dilated cardiomyopathy                            26            4.57×10^−3^
  Valine, leucine and isoleucine degradation        15            7.22×10^−3^
  Glioma                                            19            8.70×10^−3^
  Natural killer cell mediated cytotoxicity         32            0.018518
  Non-small cell lung cancer                        16            2.06×10^−2^
  Gap junction                                      23            2.30×10^−2^
  Aldosterone-regulated sodium reabsorption         13            2.45×10^−2^
  Endocytosis                                       41            2.55×10^−2^
  MAPK signaling pathway                            56            2.78×10^−2^
  Progesterone-mediated oocyte maturation           22            2.95×10^−2^
  Arrhythmogenic right ventricular cardiomyopathy   20            2.97×10^−2^
  ErbB signaling pathway                            22            3.32×10^−2^
  Fc epsilon RI signaling pathway                   20            3.81×10^−2^
  p53 signaling pathway                             18            3.84×10^−2^
  Colorectal cancer                                 21            4.23×10^−2^
  Cell adhesion molecules                           30            4.58×10^−2^
  Glycerolipid metabolism                           13            4.84×10^−2^
  B cell receptor signaling pathway                 19            4.89×10^−2^

ECM, extracellular matrix; MAPK, mitogen-activated protein kinase.
